^
    Back
    Association details:
    Biomarker:IDH1 mutation
    Cancer:Cholangiocarcinoma
    Drug:saracatinib (AZD0530) (Src kinase inhibitor, FAK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Discov
    Title:

    Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma

    Excerpt:
    Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver bile duct malignancy exhibiting frequent isocitrate dehydrogenase (IDH1/IDH2) mutations....Both IDHm ICC lines also demonstrated outlier sensitivity to saracatinib.
    DOI:
    10.1158/2159-8290.CD-15-1442